Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen

Abstract

The effect on immunogenicity of different tumor T cell epitope formulations was evaluated in vitro using nonreplicating recombinant vaccinia vector expressing two forms of the melanoma-associated MART-1/Melan-A antigen. The first recombinant virus expressed a minigene encoding a fusion product between an endoplasmic reticulum (ER)–targeting signal and the HLA-A201 binding 27–35 peptide. The second viral construct encoded the complete MART-1/Melan-A protein. The capacity of HLA-A201 cells infected with either viral construct to generate and to stimulate MART-1/Melan-A 27–35 specific cytotoxic T-lymphocytes (CTL), was comparatively characterized. The results obtained here with a tumor antigen confirmed the capacity of vaccinia virus–encoded ER-minigene to generate a very strong antigenic signal. In cytotoxicity assays, recognition of target cells infected with high amounts of both recombinant viruses with activated specific CTL clones, resulted in similar lytic activity. With regard to calcium mobilization, TCR down-regulation, IFN-γ release, and T cell proliferation assays, the targeted epitope elicited 10- to 1000-fold stronger responses. Remarkably, the immunogenic difference between the two formulations, in their respective capacity to generate CTL from naive HLA-A2 peripheral blood mononuclear cells in vitro as measured by tetramer detection, was lower (2- to 3-fold). Recombinant vectors expressing complete antigens have demonstrated their capacity to generate specific responses and such vaccines might take advantage of a broader potential of presentation. However, as demonstrated here for the HLA-A201–restricted MART-1/Melan-A immunodominant epitope, nonreplicative vaccinia virus expressing ER-targeted minigenes appear to represent a significantly more immunogenic epitope vaccine formulation. Cancer Gene Therapy (2001) 8, 655–661.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Anton LC, Yewdell JW, Bennink JR . MHC class I–associated peptides produced from endogenous gene products with vastly different efficiencies J Immunol 1997 158: 2535–2542

    CAS  PubMed  Google Scholar 

  2. Bacik I, Cox JH, Anderson R, et al . TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide J Immunol 1994 152: 381–387

    CAS  PubMed  Google Scholar 

  3. Chaux P, Luiten R, Demotte N, et al . Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1 J Immunol 1999 163: 2928–2936

    CAS  PubMed  Google Scholar 

  4. Chen W, Anton LC, Bennink JR, et al . Dissecting the multifactorial causes of immunodominance in class I–restricted T cell responses to viruses Immunity 2000 12: 83–93

    Article  CAS  Google Scholar 

  5. Conry RM, Khazaeli MB, Saleh MN, et al . Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration Clin Cancer Res 1999 5: 2330–2337

    CAS  PubMed  Google Scholar 

  6. Deng Y, Yewdell JW, Eisenlohr LC, et al . MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I–restricted peptides recognized by antiviral CTL J Immunol 1997 158: 1507–1515

    CAS  PubMed  Google Scholar 

  7. Fonteneau JF, Le Drean E, Le Guiner S, et al . Heterogeneity of biologic responses of melanoma-specific CTL J Immunol 1997 159: 2831–2839

    CAS  PubMed  Google Scholar 

  8. Hudrisier D, Kessler B, Valitutti S, et al . The efficiency of antigen recognition by CD8+ CTL clones is determined by the frequency of serial TCR engagement J Immunol 1998 161: 553–562

    CAS  PubMed  Google Scholar 

  9. Jaeger E, Bernhard H, Romero P, et al . Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo : implications for tumor vaccines with melanoma-associated antigens Int J Cancer 1996 66: 162–169

    Article  CAS  Google Scholar 

  10. Lehner PJ, Cresswell P . Processing and delivery of peptides presented by MHC class I molecules Curr Opin Immunol 1996 8: 59–67

    Article  CAS  Google Scholar 

  11. Meko JB, Yim JH, Tsung K, et al . High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12 Cancer Res 1995 55: 4765–4770

    CAS  PubMed  Google Scholar 

  12. Morel S, Levy F, Burlet-Schiltz O, et al . Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells Immunity 2000 12: 107–117

    Article  CAS  Google Scholar 

  13. Offringa R, van der Burg SH, Ossendorp F, et al . Design and evaluation of antigen-specific vaccination strategies against cancer Curr Opin Immunol 2000 12: 576–582

    Article  CAS  Google Scholar 

  14. Pardoll DM . Therapeutic vaccination for cancer Clin Immunol 2000 95: 44–62

    Article  Google Scholar 

  15. Parkhurst MR, Salgaller ML, Southwood S, et al . Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues J Immunol 1996 157: 2539–2548

    CAS  PubMed  Google Scholar 

  16. Puhlmann M, Brown CK, Gnant M, et al . Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase–deleted mutant Cancer Gene Ther 2000 7: 66–73

    Article  CAS  Google Scholar 

  17. Reynolds SR, Celis E, Sette A, et al . HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients J Immunol 1998 161: 6970–6976

    CAS  PubMed  Google Scholar 

  18. Romero P, Gervois N, Schneider J, et al . Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201–restricted Melan-A/MART-1 antigenic peptide in melanoma J Immunol 1997 159: 2366–2374

    CAS  PubMed  Google Scholar 

  19. Spagnoli GC, Schaefer C, Willimann TE, et al . Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients Int J Cancer 1995 64: 309–315

    Article  CAS  Google Scholar 

  20. Tsang KY, Zhu M, Nieroda CA, et al . Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen Clin Cancer Res 1997 3: 2439–2449

    CAS  PubMed  Google Scholar 

  21. Tsung K, Yim JH, Marti W, et al . Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light J Virol 1996 70: 165–171

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Valitutti S, Muller S, Dessing M, et al . Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy J Exp Med 1996 183: 1917–1921

    Article  CAS  Google Scholar 

  23. Valmori D, Levy F, Miconnet I, et al . Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue J Immunol 2000 164: 1125–1131

    Article  CAS  Google Scholar 

  24. Yang S, Kittlesen D, Slingluff CLJ, et al . Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3 J Immunol 2000 164: 4204–4211

    Article  CAS  Google Scholar 

  25. Yee C, Savage PA, Lee PP, et al . Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers J Immunol 1999 162: 2227–2234

    CAS  PubMed  Google Scholar 

  26. Yewdell J, Anton LC, Bacik I, et al . Generating MHC class I ligands from viral gene products Immunol Rev 1999 172: 97–108

    Article  CAS  Google Scholar 

  27. Zajac P, Oertli D, Spagnoli GC, et al . Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-1/Melan-A 27–35 epitope Int J Cancer 1997 71: 491–496

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul Zajac.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schütz, A., Oertli, D., Marti, W. et al. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen. Cancer Gene Ther 8, 655–661 (2001). https://doi.org/10.1038/sj.cgt.7700351

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700351

Keywords

This article is cited by

Search

Quick links